SAGA Diagnostics

Executive Summary

SAGA Diagnostics, founded in 2016 and headquartered in Lund, Sweden with a CLIA lab in North Carolina, is pioneering ultra-sensitive liquid biopsy technology for molecular residual disease (MRD) detection in cancer. Its flagship product, Pathlight™, is a blood-based, multi-cancer MRD test designed to detect recurrence earlier than standard imaging, enabling intervention at the most treatable stage. The company leverages proprietary digital PCR and NGS technologies to achieve industry-leading sensitivity, targeting a significant unmet need in oncology surveillance. With the global MRD testing market expected to grow rapidly, SAGA is positioned as a key innovator. The company benefits from a dual footprint in Europe and the US, facilitating clinical adoption and regulatory pathways. While still private, SAGA has potential to disrupt the post-treatment monitoring landscape. Success hinges on clinical validation, reimbursement wins, and strategic partnerships. The company's focus on early interception of recurrence aligns with the broader shift toward personalized cancer care.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical validation data for Pathlight in a multi-cancer cohort70% success
• Q3 2026Securing a strategic partnership with a major pharmaceutical or diagnostics company for commercialization50% success
• Q2 2026Completion of Series B or C funding round to scale CLIA operations and expand US market presence80% success